Non-GBC DLBCL new treatment

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30212-8/fulltext

Ibrutinib plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves event-free survival, progression-free survival, and overall survival compared with R-CHOP alone in patients younger than 60 years with untreated non-germinal centre B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL), according to a recent study.

2 thoughts on “Non-GBC DLBCL new treatment”

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s